Uveitis: Advances in understanding of pathogenesis and treatment

Current Rheumatology Reports

Volumn 8, Issue 4, 2006, Pages 260-266

  Read, Russell W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALKYLATING AGENT; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BETA INTERFERON; BEVACIZUMAB; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FLUOCINOLONE ACETONIDE; INFLIXIMAB; INTERFERON; LIPOPOLYSACCHARIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; OCTREOTIDE; PREDNISONE; PYRIMETHAMINE SULFADIAZINE; TACROLIMUS; TOLL LIKE RECEPTOR 4; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ANKYLOSING SPONDYLITIS; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BEHCET DISEASE; CATARACT; CHILDHOOD DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG IMPLANTATION; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HLA SYSTEM; HUMAN; INNATE IMMUNITY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LUNG EMBOLISM; LUPUS LIKE SYNDROME; MORBIDITY; MULTIPLE SCLEROSIS; NONHUMAN; OPTIC NEURITIS; PATHOGENESIS; PATIENT COMPLIANCE; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK REDUCTION; SUSTAINED RELEASE FORMULATION; TOXOPLASMOSIS; TREATMENT RESPONSE; UVEITIS; VIRUS INFECTION; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE; VOGT KOYANAGI SYNDROME;

EYE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; UVEITIS;

EID: 33750321159     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0006-6     Document Type: Review

References (45)

1. Gritz DC, Wong IG: Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004, 111:491-500. This article provides an accurate accounting of the incidence and prevalence of uveitis in a health maintenance organization population in Northern California.
2. Reeves SW, Sloan FA, Lee PP, Jaffe GJ: Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology 2006, 113:307.e1.
3. Suttorp-Schulten MS, Rothova A: The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996, 80:844-848.
4. Goldstein H: The reported demography and causes of blindness throughout the world. Adv Ophthalmol 1980, 40:1-99.
5. Darrell RW, Wagener HP, Kurland LT: Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962, 68:502-514.
6. Nussenblatt RB: The natural history of uveitis. Int Ophthalmol 1990, 14:303-308.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005, 140:509-516. The work of a consortium of international uveitis specialists, this is the inaugural report of what will be a series of workshops that will define uveitis and how research relating to it should be reported. This article provides basic terminology for anyone interested in the field.
8. Rodriguez A, Calonge M, Pedroza-Seres M, et al.: Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996, 114:593-599.
9. Henderly DE, Genstler AJ, Smith RE, Rao NA: Changing patterns of uveitis. Am J Ophthalmol 1987, 103:131-136.
10. McCannel CA, Holland GN, Helm CJ, et al.: Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996, 121:732-733.
11. Merrill PT, Kim J, Cox TA, et al.: Uveitis in the southeastern United States. Curr Eye Res 1997, 16:865-874.
12. Pivetti-Pezzi P, Accorinti M, La Cava M, et al.: Endogenous uveitis: an analysis of 1,417 cases. Ophthalmologica 1996, 210:234-238.
13. de Groot-Mijnes JD, de Visser L, Rothova A, et al.: Rubella virus is associated with fuchs heterochromic iridocyclitis. Am J Ophthalmol 2006, 141:212-214.
14. Touge C, Agawa H, Sairenji T, Inoue Y: High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis. Arch Virol 2005, 151:895-903.
15. Chang JH, McCluskey PJ, Wakefield D: Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol 2006, 90:103-108.
16. Read RW, Szalai AJ, Vogt SD, et al.: Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res 2006, 82:389-394.
17. Holland GN, Lewis KG: An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 2002, 134:102-114.
18. Soheilian M, Sadoughi MM, Ghajarnia M, et al.: Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005, 112:1882-1884. Prospective trials in uveitis are rare, thus one dealing with the most common form of posterior uveitis is important. This provides evidence that a more convenient medical regimen is equally efficacious to the classic, but more cumbersome (and toxic) regimen.
19. Jabs DA, Rosenbaum JT, Foster CS, et al.: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001, 131:679.
20. Okada AA: Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005, 13:335-351.
21. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al.: Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004, 138:373-380.
22. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005, 52:2478-2484.
23. Ribi C, Sztajzel R, Delavelle J, Chizzolini C: Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry 2005, 76:1733-1735.
24. Lanthier N, Parc C, Scavennec R, et al.: Infliximab in the treatment of posterior uveitis in Behcet's disease. Long term follow up in four patients. Presse Med 2005, 34:916-918.
25. Ohguro N, Yamanaka E, Otori Y, et al.: Repeated intravitreal triamcinolone injections in Behcet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol 2006, 141:218-220.
26. Westfall AC, Osborn A, Kuhl D, et al.: Acute endophthalmitis incidence: intravitreal triamcinolone. Arch Ophthalmol 2005, 123:1075-1077.
27. Moshfeghi DM, Kaiser PK, Bakri SJ, et al.: Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2005, 36:24-29.
28. Becker MD, Heiligenhaus A, Hudde T, et al.: Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 2005, 89:1254-1257.
29. Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, Epub ahead of print.
30. Richards JC, Tay-Kearney ML, Murray K, Manners P: Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol 2005, 33:461-468.
31. Rajaraman RT, Kimura Y, Li S, et al.: Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006, 113:308-314.
32. Smith JA, Thompson DJ, Whitcup SM, et al.: A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23. This article provides evidence that etanercept is not effective for uveitis related to juvenile idiopathic arthritis.
33. Read RW, Yu F, Accorinti M, et al.: Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2006, in press.
34. Bykhovskaya I, Thorne JE, Kempen JH, et al.: Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol 2005, 140:674-678.
35. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451.
36. Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123:903-912. This article provides evidence that infliximab is effective for uveitis, but a high incidence of adverse events was experienced.
37. Siepmann K, Huber M, Stubiger N, et al.: Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. A retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2005, Epub ahead of print.
38. Thorne JE, Jabs DA, Qazi FA, et al.: Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005, 112:1472-1477.
39. US Food and Drug Administration: Center for Drug Evaluation and Research priority drug and biologic approvals in calendar year 2005. http://www.fda.gov/ cder/rdmt/NDAPriority05.htm. Accessed March 16, 2006.
40. Jaffe GJ, McCallum RM, Branchaud B, et al.: Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005, 112:1192-1198.
41. Jaffe G, Martin D, Callanan D, et al.: Fluocinolone acetonide intravitreal implant to treat posterior uveitis: 2-year results of a multi-center clinical trial [abstract 2386]. ARVO 2005, http://www.arvo.org.
42. Jaffe G, Martin D, Callanan D, et al.: Fluocinolone acetonide intravitreal implant to treat posterior segment uveitis: 3-year results of a multi-center clinical trial [abstract 1523]. ARVO 2006, http://www.arvo.org.
43. Multicenter Uveitis Steroid Treatment (MUST) Trial. http:// clinicaltrials.gov. Accessed March 20, 2006.
44. Nussenblatt RB, Kim J, Thompson DJ, et al.: Vitamin E in the treatment of uveitis-associated macular edema. Am J Ophthalmol 2006, 141:193-194.
45. Papadaki T, Zacharopoulos I, Iaccheri B, et al.: Somatostatin for uveitic cystoid macular edema (CME). Ocul Immunol Inflamm 2005, 13:469-470.